Palvella Therapeutics (PVLA) Expected to Post Earnings on Thursday

Palvella Therapeutics (NASDAQ:PVLA) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Palvella Therapeutics to post earnings of ($1.78) per share and revenue of $0.02 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). On average, analysts expect Palvella Therapeutics to post ($6.45) EPS for the current fiscal year and ($8.61) EPS for the next fiscal year.

Palvella Therapeutics Stock Performance

Shares of PVLA opened at $146.15 on Friday. The firm has a fifty day moving average of $141.47 and a 200-day moving average of $126.70. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -30.26 and a beta of -0.27. Palvella Therapeutics has a 1 year low of $71.55 and a 1 year high of $161.38.

Insider Activity at Palvella Therapeutics

In related news, Director Christopher P. Kiritsy sold 313 shares of Palvella Therapeutics stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the transaction, the director owned 250 shares of the company’s stock, valued at approximately $39,250. This trade represents a 55.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Kathleen Goin sold 4,313 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $124.58, for a total transaction of $537,313.54. Following the completion of the transaction, the chief operating officer directly owned 2,165 shares in the company, valued at approximately $269,715.70. This trade represents a 66.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,056 shares of company stock valued at $8,756,946 over the last ninety days. Insiders own 17.20% of the company’s stock.

Analysts Set New Price Targets

PVLA has been the topic of several analyst reports. Canaccord Genuity Group set a $232.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating on shares of Palvella Therapeutics in a research report on Tuesday, October 20th. Raymond James Financial set a $226.00 target price on Palvella Therapeutics in a research report on Friday, October 16th. Truist Financial set a $207.00 target price on Palvella Therapeutics in a research report on Wednesday, August 5th. Finally, William Blair began coverage on Palvella Therapeutics in a research note on Friday, October 16th. They set an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $209.79.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.